

**THE UNIVERSITY OF TEXAS AT TYLER  
INSTITUTIONAL BIOSAFETY COMMITTEE  
September 17, 2025**

**MEMBERS' PRESENT:**

Dr. Galina Florova – IBC Chair – Professor Cellular and Molecular Biology  
Dr. Wei-Chin Ho – IBC Member – Assistant Professor of Biology  
Dr. Dustin Patterson – IBC Member - Professor of Chemistry & Biochemistry  
Dr. Hua Tang – IBC Member – Professor of Biochemistry  
Ms. Beth R. Filla – Local Non-affiliated member - Bachelor of Science in Agricultural Development  
Mr. Chris Frydenlund – Senior Manager Research Compliance  
Michael Medford - P.E., CPESC

**OTHERS PRESENT:**

Recorder Secretary

**MEMBERS ABSENT:**

Dr. Buka Samten

**OLD BUSINESS:**

The committee continues to meet via TEAMS.

**I. CALL TO ORDER:**

The meeting was called to order at 1:32 pm

**II. APPROVAL OF MINUTES:**

Minutes from July 16, 2025, IBC meeting were approved with minor modifications.

- Update Dr. Patterson title and italicized the word *E. coli*.

The committee reviewed the minutes, and a motion was made by Dr. Dustin Patterson to approve the minutes. Mr. Chris Frydenlund seconded the motion.

**APPROVE: 6      ABSTAIN: 0      OPPOSE: 0**

**III. REVIEW OF IORRC MINUTES:**

The minutes from the June 18, 2025, meeting were reviewed by the IBC.

**IV. CHAIRMAN'S REPORT:**

None

**V. OLD BUSINESS:**

None

**VI. NEW BUSINESS:**

## Protocol and Amendments for Review

### Recombinant DNA protocols

#### 1. rDNA Protocol 265

Protocol	(PI)	Project Title	BSL	ABSL	Campus
265	Dr. Xia Guo	"Novel Genes in Inflammatory Diseases"	BSL2	N/A	UTHSC

**Project overview:** We will express or delete genes in different cell types or in mice to study the function of these genes in diseases, chronic inflammation, and fibrosis.

Applicable NIH Guidelines: Section II-A-3, III, and IV-B-2-b

Major points of discussion:

- Agent characteristics (pathogenicity)
- Types of manipulations planned.
- Source(s) of the nucleic sequences (species, manufacturer)
- Nature of the nucleic acid sequences (structural gene)
- Host(s) and vector(s) to be used
- Whether an attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced.

**The following will be communicated to the PI:**

#### Page 5

**A. Host** Please clarify the pathogenicity of the human cell lines that you plan to purchase from ATCC or Lonza. Please clarify why two animal protocols are referenced on the first page, yet only one is noted in the host section. Are you planning to use animals on both protocols?

**B. Vector** Replication section – Please clarify replication requirements for the vectors. Clarify which vectors for animal study you are planning to use and update the vector section.

**C. Gene** Please clarify the source of the gene. Please confirm the name of the last gene on the table. Please clarify if SNX29P2, a pseudogene, has functionality.

#### Page 6

**F. Risks to humans.** Please describe what kind of PPE/other measures you are planning to use to protect the personnel that will be working with these vectors.

**7A. Chemicals** Please clarify if you are planning to propagate and/or to purify either the vectors or viruses associated with those vectors and if indeed no chemicals are involved.

**7B. Animals** Please clarify which exact vector will be used in animals. Please spell out the vector's name in **section B**. Please also address whether animals show signs of clinical disease, and whether the agents be shed/excreted by the infected animals.

The committee reviewed the protocol, and a motion was made by Dr. Ho to approve the protocol pending corrections. Dr. Tang seconded the motion.

**APPROVE: 7      ABSTAIN: 0      OPPOSE: 0**

## Addendum Recombinant DNA protocol 250-1

### 1. rDNA Protocol 250-1

Protocol	(PI)	Project Title	BSL	ABSL	Campus
250-1	Dr. L. Vijaya Mohan Rao	“Elucidation of hemostatic, thrombotic, and inflammatory mechanisms in health and disease conditions.”	BSL2	N/A	UTHSC

**Project overview:** The primary objective of the research is to understand initiation and regulation of blood coagulation in hemostasis, thrombosis, and inflammation and how proteins involved in the blood coagulation contribute to the pathogenesis of various diseases, particularly bacterial infection/inflammation, lung injury, atherosclerosis, and cancer. To elucidate how various infections and other diseases processes affect blood coagulation and vice versa.

**Differences between the new and the original protocol:** We are adding the following investigators to the protocol. Ankith Sherapura, Pavan Sonnenahalli Rudramurthy, Suchitha GhiridharaPrema, Venkata Kiran Mandlem, Shabbir Ansari, and Atrayee Bhattacharya. Please remove Kaushik Das and Xaiolu Xie, who left the university.

**Explain and justify the addendum in terms of the objective(s) stated above:** There is no significant deviation in terms of the objectives of the original protocol. We are adding new investigators joined the lab after the approval of original protocol. Shabbir Ansari and Atrayee are new faculty members who will be collaborating in helping us to achieve the stated objective.

The committee reviewed the addendum, and a motion was made by Ms. Beth Filla to approve it. Dr. Tang seconded the motion.

**APPROVE: 7      ABSTAIN: 0      OPPOSE: 0**

### VII. ADJOURNMENT:

The meeting was adjourned at 2:13 p.m.

*Galina Florova*

---

Galina Florova, Ph.D. – Chair  
Institutional Biosafety Committee  
Recording Secretary